Relating to a study on the use of psychedelic therapies in the treatment of certain conditions.

SB 3005 directs Texas' Department of State Health Services to study the use of psychedelic therapies (including MDMA, psilocybin, and ketamine) for treating PTSD, depression, and related conditions. The study requires reviewing clinical trials, FDA actions, treatment guidelines, and patient access barriers like provider availability and affordability. The department must consult with Baylor College of Medicine and UT Austin's Dell Medical School and submit a report with recommendations by December 1, 2026. This bill does not change current laws or provide immediate access to psychedelic therapies - only studies their potential use after future FDA approval. It expires September 1, 2027, and affects no current patients or providers.